Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data

Table 6 Unadjusted and adjusted HR of severe hypoglycemia by medication class - Standard group participants ⁽¹⁾

Medication Use in Interval Antecedent to Ascertainment of Event Status	Unadjusted			Adjusted⁽²⁾
	HR	95% CI	P value	HR	95% CI	P value
Sulfonylurea	0.51	(0.37, 0.69)	<.0001	0.85	(0.6, 1.20)	0.36
Biguanide	0.54	(0.40, 0.74)	<.0001	0.73	(0.53, 1.00)	0.05
TZDs	1.47	(1.09, 1.98)	0.01	1.83	(1.35, 2.48)	<.0001
AGIs	1.48	(0.54, 4.01)	0.44	1.45	(0.52, 4.03)	0.48
Meglitinide	1.34	(0.85, 2.10)	0.21	1.50	(0.93, 2.42)	0.10
Incretin	1.84	(0.58, 5.86)	0.30	1.80	(0.56, 5.74)	0.32
Bolus Insulin	2.25	(1.63, 3.09)	<.0001	1.68	(1.14, 2.47)	0.01
Basal Insulin	2.72	(1.95, 3.79)	<.0001	0.85	(0.60, 1.20)	0.36
Pre-Mixed Insulin	2.24	(1.56, 3.23)	<.0001	0.73	(0.53, 1.00)	0.05

⁽¹⁾ Hazard ratio for use of medication as part of glycemia medication regimen compared to participants who were not prescribed medication. All results control for the following baseline covariates: age, gender, race, education, time since diabetes diagnosis, history of neuropathy/nerve problems, BMI, A1C, albumin to creatinine ratio, serum creatinine, LDL-C, and factors used to stratify randomization (treatment groups within the BP and Lipid trials and the presence of clinical cardiovascular disease).
⁽²⁾ Adjusted for baseline covariates and other listed glycemia medications.

ISSN: 1472-6823